Ado-trastuzumab emtansine Intravenous

Uncategorized

Ado-trastuzumab emtansine Intravenous

What is Ado-trastuzumab emtansine Intravenous
?

Ado-trastuzumab emtansine (Kadcyla) is a targeted therapy drug used to treat HER2-positive breast cancer. It is a combination of the drug trastuzumab (Herceptin) and the chemotherapy drug emtansine (DTIC-dome). Ado-trastuzumab emtansine is given intravenously (by vein).

Benefits of Ado-trastuzumab emtansine Intravenous
and Its Uses.

Ado-trastuzumab emtansine is a monoclonal antibody that is designed to specifically bind to the HER2 receptor on tumor cells. It is used to treat breast cancer that has spread to other parts of the body (metastatic breast cancer).

Ado-trastuzumab emtansine is given as an intravenous (IV) infusion. It is usually given in a hospital or clinic setting.

The most common side effects of ado-trastuzumab emtansine include fever, chills, headache, tiredness, and nausea.

Side Effects and Dosage of Ado-trastuzumab emtansine Intravenous

Ado-trastuzumab emtansine intravenous (Kadcyla) is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Ado-trastuzumab emtansine intravenous is used to treat HER2-positive breast cancer.

Ado-trastuzumab emtansine intravenous may also be used for purposes not listed in this medication guide.

Do not use ado-trastuzumab emtansine intravenous if you are pregnant. It could harm the unborn baby.

You should not use ado-trastuzumab emtansine intravenous if you are allergic to it.

Before you receive ado-trastuzumab emtansine intravenous, tell your doctor if you have:

kidney disease;

liver disease;

heart disease;

a history

Category: Uncategorized
Posts created 12429

Leave a Reply

Your email address will not be published.

Related Posts

Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top